GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG ‐1401
International Journal of Urology · 2024
DOI: 10.1111/iju.15371 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Urology, 2024. Verfasst von Akira Yokomizo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Harasanshin Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Astellas Pharma.
Abstract (Originalsprache)
Objectives
To compare the effectiveness and safety of gonadotropin‐releasing hormone (GnRH) antagonist monotherapy to combined androgen blockade (CAB) with a GnRH agonist and bicalutamide in patients with advanced hormone‐sensitive prostate cancer (HSPC).
Methods
The study was conducted as KYUCOG‐1401 trial (UMIN000014243) and enrolled 200 patients who were randomly assigned to either group A (GnRH antagonist monotherapy followed by the addition of bicalutamide) or group B (CAB by a GnRH agonist and bicalutamide). The primary endpoint was PSA progression‐free survival. The secondary endpoints were the time to CAB treatment failure, radiographic progression‐free survival, overall survival, changes in serum parameters, including PSA, hormones, and bone and lipid metabolic markers, and adverse events.
Results
PSA progression‐free survival was significantly longer in group B (hazard ratio [HR], 95% confidence interval [CI]; 1.40, 1.01–1.95, p = 0.041). The time to CAB treatment failure was slightly longer in group A (HR, 95% CI; 0.80, 0.59–1.08, p = 0.146). No significant differences were observed in radiographic progression‐free survival or overall survival. The percentage of patients with serum testosterone that did not reach the castration level was higher at 60 weeks ( p = 0.046) in group A. No significant differences were noted in the serum levels of bone metabolic or lipid markers between the two groups. An injection site reaction was more frequent in group A.
Conclusions
The present results support the potential of CAB using a GnRH agonist and bicalutamide as a more effective treatment for advanced HSPC than GnRH antagonist monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Harasanshin Hospital, Fukuoka, Japan.
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Urology Department, Saga-Ken Medical Centre Koseikan, Saga, Japan.
- Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
- Department of Urology, University of Miyazaki, Miyazaki, Japan.
- Department of Urology, University of Fukui, Fukui, Japan.
ORCID-Profile: Akira Yokomizo, Masaki Shiota, Hiroaki Matsumoto, Naoki Terada, Naohiro Fujimoto, Shigetaka Suekane
Förderung
- Astellas Pharma
Zitieren
APA
Yokomizo, A., Shiota, M., Morokuma, F., Eto, M., Matsuyama, H., Matsumoto, H., Kamoto, T., Terada, N., Kawahara, K., Enokida, H., Tatarano, S., Fujimoto, N., Higasijima, K., Sakai, H., Hakariya, T., Igawa, T., Suekane, S., Kamba, T., Sugiyama, Y., …, & Naito, S. (2024). GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG ‐1401. International Journal of Urology. https://doi.org/10.1111/iju.15371
Vancouver
Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, et al. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG ‐1401. International Journal of Urology. 2024. doi:10.1111/iju.15371
BibTeX
@article{Yokomizo2024,
author = {Yokomizo, Akira and Shiota, Masaki and Morokuma, Futoshi and Eto, Masatoshi and Matsuyama, Hideyasu and Matsumoto, Hiroaki and Kamoto, Toshiyuki and Terada, Naoki and Kawahara, Kazuya and Enokida, Hideki and Tatarano, Shuichi and Fujimoto, Naohiro and Higasijima, Katsuyoshi and Sakai, Hideki and Hakariya, Tomoaki and Igawa, Tsukasa and Suekane, Shigetaka and Kamba, Tomomi and Sugiyama, Yutaka and Kishimoto, Junji and Naito, Seiji},
title = {GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG ‐1401},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15371}
}
EUVIMED